Overcoming drug-resistant tuberculosis

This article reviews the escalating issue of TB resistance, particularly to first and second-line treatments such as rifampicin and isoniazid, and the broader implications for health systems globally. The growing prevalence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) TB strains demands a multipronged approach, integrating robust diagnostic processes, effective disease management, and comprehensive public health initiatives.
Recent statistics highlight a troubling trend, with only 71% of diagnosed pulmonary TB cases being tested for rifampicin resistance, revealing about 132,222 cases of MDR/RR-TB and 25,681 cases of pre-XDR or XDR-TB. These figures underscore the need for enhanced diagnostic and therapeutic protocols to curb the transmission and evolution of drug-resistant TB. The review discusses the pivotal role of innovative diagnostic technologies, including rapid molecular tests and point-of-care solutions, in improving the detection and management of drug-resistant TB.
The integration of novel therapeutic agents, shorter treatment regimens, and targeted drug discovery efforts are crucial for addressing the biological mechanisms underpinning resistance. Furthermore, the review highlights the importance of a holistic approach to TB management, which includes strengthening health systems, enhancing patient adherence to treatment, and deploying preventive measures among at-risk populations.